Genedrive Share Discussion Threads

[snowy20] 16/6/2022 09:18

NICE to evaluate the Genedrive® MT-RNR1 Test under their Diagnostics Assessment Programme



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS.



An independent advisory committee considers the evidence provided, makes draft recommendations for public consultation and ultimately makes final recommendations for publication in NICE guidance. The guidance produced is used by NHS commissioners, practitioners, healthcare operational managers and purchasing and procurement organisations.



genedrive's assay is the world's first rapid point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive® MT-RNR1 test.

[snowy20] 16/6/2022 09:15

50k buyer filling up with shares yesterday .50k buyer filling up more shares this day .

[snowy20] 16/6/2022 09:13

Important RNS .Progressing well. When traders gone thinking long term buyers start filling up .

[yasyas1] 16/6/2022 08:32

If NICE approve then all nhs trusts have to use

[boysie72] 16/6/2022 08:08

Has Snowy overslept?

[boysie72] 16/6/2022 07:19

Great RNS. This is not just about this product, if you are a longer term investor then you will see that the landscape for GDR is getting bigger, the sales will come. Ignore the traders, they are looking to make pennies, just solely look at the company and the the 2 huge achievements with the last 2 products.

[dipa11] 16/6/2022 07:07

Today press release

[snowy20] 15/6/2022 20:55

50k x 3 buys ,Watch for next rise .

[snowy20] 15/6/2022 20:54

GDR exhibiting at another exhibition today . The difference after sales people recruited .
.
Watch for next move up .

[iamthemagnificent] 15/6/2022 16:02

snowy20 - 22 Dec 2021 - 10:06:09 - 29008 of 2982 Glaxosmithkline - The recovery
moved money to gdr , gdr looking so hot for 2022 with their new 7,5 minute poc covid test



So, let's see how you did, snowy20
GSK after you sold and moved into GDR is UP approx 13% over that period
GDR is DOWN approx 50-70% since you started ramping with hundreds (thousands?) of posts

Best ignored IMHO. GSK is still by far the better investment !

[milanr] 15/6/2022 15:16

Will repeat:FINANCIAL HIGHLIGHTS -- No revenue in the period, (31 Dec 2020: GBP0.4m) owing to delayed product development -- Operating loss of GBP2.8m (31 Dec 2020: GBP2.9m) -- R&D spend reduced to GBP1.9m (31 Dec 2020: GBP2.3m)

[snowy20] 15/6/2022 14:59

Watch the buyers who buy before end of this day .WHO not want to miss out if rns .

[snowy20] 15/6/2022 14:57

Catch up with progress
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.




Watch for HVC RNS & AIHL RNS .High chance quid when NHS sales RNS .

NHS update Due .



Into news time .If not this day .Watch for news soon

[snowy20] 15/6/2022 14:55

Minister for Innovation, Lord Kamall, said: “Genomics is changing the future of healthcare – from detecting new variants of Covid to enabling more targeted treatment of illness.

“This innovative new test has the potential to prevent life altering and preventable side effects for babies and keep the NHS ahead of the curve in delivering state of the art care.

“The UK continues to lead the way in genomics expertise and is paving the way for earlier diagnosis of conditions in children and faster access to the right treatment”.

[snowy20] 15/6/2022 14:54

Mike Hobday, Director of Policy and Campaigns at the National Deaf Children’s Society, said: “The National Deaf Children’s Society welcomes the publication of this important study. The introduction of a rapid test to identify susceptibility to deafness caused by the antibiotic gentamicin will be greatly valued by many families of newborn babies.

“Up to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer”

[snowy20] 15/6/2022 14:54

Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, said: “Genomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage – not only in intensive care but across our services.

“It also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.”

Professor Newman, who is Associate Lead, Hearing Health Genomic Solutions at NIHR Manchester Biomedical Research Centre (BRC), said the team had successfully transferred the accuracy of the machine in the lab to working effectively in a ward. At the same time, clinicians adapted quickly to incorporate the test into their routine care for very sick children in the neonatal ward.

The idea for the test came five years ago, and trials started in 2020 with further adaptations and fine-tuning so that the current machine, which is called the Genedrive System, is now fully CE certified to be used in a clinical setting.

Study results were published in JAMA Pediatrics – the top-ranked paediatrics journal in the world – last week.

Backed by £900,000 funding from the National Institute for Health Research (NIHR) and support from the charity Royal National Institute for Deaf People, the Genedrive System, which costs £80 per baby, was developed by Genedrive, a start-up based at the University of Manchester. It was developed in close collaboration with Professor Newman’s team at Manchester Biomedical Research Centre.

[snowy20] 15/6/2022 14:53

Professor Bill Newman, a consultant in genomic medicine at Manchester University NHS Foundation Trust and Professor of Translational Genomic Medicine at the University of Manchester, led the Pharmacogenetics to Avoid Loss of Hearing (PALoH) study.

He said: “I am absolutely thrilled with the success of the study, and that this testing is now going to be used in three of our Trust’s Neonatal Intensive Care Units – it’s actually going to make a real difference so babies are not going to lose their hearing for a preventable reason.

“The trial demonstrated that you can deploy rapid genetic testing in a clinical setting, and that the tests can be carried out within the ‘golden hour’ when severely unwell babies should be treated with antibiotics.”

Following the completion of the ground-breaking study, the NHS Genomic Medicine Service Alliance and the NHS will be exploring how this technology can be launched as part of a clinical service through the NHS Genomic Medicine Service.

[milanr] 15/6/2022 13:53

FINANCIAL HIGHLIGHTS -- No revenue in the period, (31 Dec 2020: GBP0.4m) owing to delayed product development -- Operating loss of GBP2.8m (31 Dec 2020: GBP2.9m) -- R&D spend reduced to GBP1.9m (31 Dec 2020: GBP2.3m)

[milanr] 15/6/2022 13:50

Sales ZERO, read last trading statement

[snowy20] 15/6/2022 13:03

GDR exhibiting at another exhibition today . The difference after sales people recruited .